PIQRAY® (alpelisib) | PIK3CA-mutated advanced breast cancer
slide overlay image

Explore podcasts and videos

PIQRAY Highlights podcast
Talking PIQRAY Podcast Series
Check out the first season of Talking PIQRAY, a podcast series dedicated to exploring data, patient management considerations, and more.
See podcasts
PIQRAY mechanism of action
PIQRAY Videos
Learn more about PIQRAY from multiple experts in the treatment of HR+/HER2- aBC. Topics include clinical trial data, mechanism of action, and patient management.
Watch videos
slide overlay image

Learn patient
management strategies

PIQRAY Patient Management Tool icon
Keeping TRAQ with PIQRAY:
Patient Management Tool
Click through relevant
considerations for selected adverse reactions
Explore the tool
Downloadable management checklists icon
Downloadable management
checklists
Stay up to date with key
information for treatment
management
Start your checklist

Indication from Summary of Product Characteristics

PIQRAY is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)‐positive, human epidermal growth factor receptor 2 (HER2)‐negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as monotherapy.
slide overlay image
Patients with a
PIK3CA mutation
face a poor prognosis1
Learn more about the PIK3CA mutation
~40% of patients with HR+/HER2- aBC have a PIK3CA mutation
slide overlay image
PIQRAY addresses
PIK3CA mutations by
targeting PI3Kα,
a key upstream
component of the
PI3K pathway3,4
Find out how
PIQRAY works
play button
PIQRAY mechanism of action PIQRAY mechanism of action
slide overlay image
Nearly doubled mPFS
in patients with a
PIK3CA mutation4,5
See the efficacy
of PIQRAY
PIQRAY median progression-free survival chart
Downloadable management checklists icon
Downloadable management
checklists
Stay up to date with key information
for treatment management
Start your checklist
See the patient management tool, treatment management checklists, and more PIQRAY patient resources.
PIQRAY Patient Management Tool icon
Keeping TRAQ with PIQRAY:
Patient Management tool
Click through relevant
considerations for selected adverse reactions
Explore the tool
Progression free chart image Progression free chart image
References: 1. Mosele F,
Stefanovska B,
Lusque A,
et al.
Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer. Ann Oncol. 2020;31(3):377-386. 2. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61-70. 3. Chalhoub C, Baker SJ. PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol. 2009;4:127-150. 4. Piqray® (alpelisib) EU Summary of Product Characteristics. Novartis; May 2021. 5. André F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med. 2019;380(20):1929-1940.